Evidence map›Paper›PMID 28352658›Full record

ArticleJCI insight2017

Priming is key to effective incorporation of image-guided thermal ablation into immunotherapy protocols.

Matthew T Silvestrini, Elizabeth S Ingham, Lisa M Mahakian, Azadeh Kheirolomoom, Yu Liu, Brett Z Fite, Sarah M Tam, Samantha T Tucci, Katherine D Watson, Andrew W Wong and 5 more

Abstract read
In one paragraph

Article in JCI insight, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Guideline
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Sex parity in stimulation of murine lymphocyte trafficking in response to fever-range systemic thermal therapy.International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2025
    Article
  13. Article
  14. Preclinical study of TLR stimulation combined PD-1 antibody enhance the therapeutic effect of microwave ablation on NSCLC.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Article
  15. Article
  16. Review
  17. Article
  18. Overview of Therapeutic Ultrasound Applications and Safety Considerations: 2024 Update.Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine · 2025
    Review
  19. Review
  20. Article

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Matthew T SilvestriniDepartment of Biomedical Engineering.
Elizabeth S InghamDepartment of Biomedical Engineering.
Lisa M MahakianDepartment of Biomedical Engineering.
Azadeh KheirolomoomDepartment of Biomedical Engineering.
Yu LiuDepartment of Biomedical Engineering.
Brett Z FiteDepartment of Biomedical Engineering.
Sarah M TamDepartment of Biomedical Engineering.
Samantha T TucciDepartment of Biomedical Engineering.
Katherine D WatsonDepartment of Biomedical Engineering.
Andrew W WongDepartment of Biomedical Engineering.
Arta M MonjazebDepartment of Radiation Oncology.
Neil E HubbardCenter for Comparative Medicine.
William J MurphyDepartment of Dermatology, Institute for Regenerative Cures, University of California, Davis, California, USA.
Alexander D BorowskyCenter for Comparative Medicine.
Katherine W FerraraDepartment of Biomedical Engineering.

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI Laura Marcu · 2002 to 2026
$84.9M
Ultrasound imaging and enhanced therapeutic responseR01CA134659 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI FERRARA, KATHERINE W · 2009 to 2017
$4.4M
Image-guided ultrasound therapy and drug delivery in pancreatic cancerR01CA210553 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI FERRARA, KATHERINE W · 2016 to 2020
$3.2M
Optimized ultrasound-enhanced immunotherapyR01CA199658 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI FERRARA, KATHERINE W · 2015 to 2019
$2.5M
Predoctoral Training in Pharmacological SciencesT32GM099608 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HELL, JOHANNES W · 2012 to 2021
$2.2M
Shared LSRII Cytometer Equipment Application - UC Davis Stem Cell ProgramS10RR026825 · NCRR · UNIVERSITY OF CALIFORNIA AT DAVIS · PI NOLTA, JAN A. · 2010 to 2010
$500k
EXTRAMURAL RESEARCH FACILITIES CONSTRUCTIONC06RR012088 · NCRR · UNIVERSITY OF CALIFORNIA DAVIS · PI CURRY, FITZ-ROY E · 1996 to 1996
–
NCI NIH HHS P30 CA093373NCI NIH HHS R01 CA134659NCI NIH HHS R01 CA199658NCI NIH HHS R01 CA210553NCRR NIH HHS C06 RR012088NCRR NIH HHS S10 RR026825NIGMS NIH HHS T32 GM099608
6 · The paper itself

Abstract

Focal therapies play an important role in the treatment of cancers where palliation is desired, local control is needed, or surgical resection is not feasible. Pairing immunotherapy with such focal treatments is particularly attractive; however, there is emerging evidence that focal therapy can have a positive or negative impact on the efficacy of immunotherapy. Thermal ablation is an appealing modality to pair with such protocols, as tumors can be rapidly debulked (cell death occurring within minutes to hours), tumor antigens can be released locally, and treatment can be conducted and repeated without the concerns of radiation-based therapies. In a syngeneic model of epithelial cancer, we found that 7 days of immunotherapy (TLR9 agonist and checkpoint blockade), prior to thermal ablation, reduced macrophages and myeloid-derived suppressor cells and enhanced IFN-γ-producing CD8

Indexed as

Clinical ProtocolsAnimalsCD8-Positive T-LymphocytesCell Line, TumorCombined Modality TherapyImmunotherapyLymphocytes, Tumor-InfiltratingMammary Neoplasms, ExperimentalMiceProgrammed Cell Death 1 ReceptorTumor MicroenvironmentPdcd1 protein, mouseProgrammed Cell Death 1 Receptor

Identifiers

PMID28352658
PMCPMC5358490

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.